Scalper1 News
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called drisapersen. Drisapersen succeeded in its phase-two trial but failed its phase three, causing partner GlaxoSmithKline (GSK) to end their relationship. At BioMarin’s investor day on Dec. 10, executives Scalper1 News
Scalper1 News